| |
| | HIV Drug Resistance Program, National Cancer Institute — Sarah Palmer, Ph.D., Publications |
 | | Palmer, S., Margot, N., Gilbert, H., Shaw, N., Buckheit, R., Jr., and Miller, M. (2001) Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. |
 | | Palmer, S., Alaeus, A., Albert, J., and Cox, S. (1998) Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates. |
 | | Palmer, S., and Cox, S. (1997) Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea. |
| www.retrovirus.info /Palmer_pub.html (769 words) |
|